American Century Companies’s SAB Biotherapeutics SABS Stock Holding History
Bought
Maintained
Sold
Other funds holding SABS
CP
VC
PA
RCM
CC
American Century Companies's SABS Position: Q2 2026 in Review
American Century Companies increased its SAB Biotherapeutics (SABS) stake by 126% in Q2 2026, buying an estimated $176K and bringing the position to 84,685 shares worth $330K. The position accounts for ﹤0.01% of the portfolio, ranked #2688.
American Century Companies first reported a position in SABS in Q1 2026 and has held it in 2 quarters since. 87 funds tracked by Wall St. Rank hold SABS as of Q2 2026.
- American Century Companies held 84,685 shares of SAB Biotherapeutics worth $330K as of Q2 2026.
- American Century Companies bought 47,230 SAB Biotherapeutics shares in Q2 2026, an estimated $176K.
- SAB Biotherapeutics made up ﹤0.01% of American Century Companies's portfolio in Q2 2026, its #2688 holding.
- American Century Companies first reported a position in SAB Biotherapeutics in Q1 2026 and has held it in 2 quarters since.
- 87 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.
Based on American Century Companies's 13F filing for Q2 2026, filed 12 Aug 2026.